From the American Academy of Ophthalmology
News from the FSO
Florida Society of Ophthalmology’s Proposals Receive Approval Regarding Inclusion and Scope of Practice Expansion
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
The U.S. Food and Drug Administration has approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema. The drug’s safety and effectiveness to treat DME were established in two clinical studies that showed a 34 to 45 percent improvement in patients treated monthly with 0.3 mg of Lucentis over a two-year period. Ophthalmologists should check with their Medicare carriers to determine coverage for Lucentis to treat DME.
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
Pages
Upcoming Events
In the News...
